<DOC>
	<DOC>NCT01240187</DOC>
	<brief_summary>The purpose of this study is to investigate the bioequivalence between 6 x 2 mg tablets and one 12 mg tablet of perampanel in healthy subjects.</brief_summary>
	<brief_title>A Study to Demonstrate Bioequivalence Between 6 x 2 mg Tablets of Perampanel and a Single 12 mg Tablet of Perampanel in Healthy Subjects</brief_title>
	<detailed_description>A Single Centre, open label, 2-period, 2-sequence crossover bioequivalence study in one group of 28 subjects.</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<criteria>Healthy male or female subjects aged between 1855 years. BMI of 1832 kg/m ^2. Willing and able to provide written informed consent. Exclusion criteria: Subjects taking prescribed or over the counter (OTC) medications in 2 weeks prior to screening. Subjects on special diets or dietary aids known to modulate drug metabolizing enzymes. Subjects who have taken inhibitor of CYP450 within 2 weeks of first dose. Subjects who have received any experimental drug in the 12 weeks prior to study drug treatment. Subjects with a history of alcohol abuse or who drink more than the recommended number of alcohol units per week. Subjects who consume more than five caffeinated beverages per day. Subjects who smoke more than 5 cigarettes per day. Subjects with a history of drug abuse or who have a positive urine drug screening test. Women who do not agree to use two methods of contraception.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>epilepsy</keyword>
</DOC>